VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

06 12月 2021 07:00:01 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

19 11月 2021 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

17 11月 2021 15:11:04 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

25 10月 2021 15:58:33 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

20 10月 2021 19:38:40 条件 Nasdaq GlobeNewswire